Developing a vaccine for advanced lung cancer driven by the ALK gene
Project 1
This study is testing a new vaccine designed to help people with advanced lung cancer caused by the ALK gene by boosting their immune system to better fight the cancer, especially for those who haven't responded well to other treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10891395 on NIH RePORTER |
What this research studies
This research focuses on creating a therapeutic vaccine specifically for patients with advanced non-small cell lung cancer (NSCLC) that is driven by the ALK gene. The approach involves identifying specific peptides from the ALK protein that can stimulate the immune system to target and destroy cancer cells. By enhancing the body's natural immune response, the goal is to improve treatment outcomes for patients who have developed resistance to existing therapies. The research will utilize advanced immunoproteomic analysis to ensure the vaccine is tailored to effectively activate the immune system against ALK-positive tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with advanced ALK-positive non-small cell lung cancer.
Not a fit: Patients with non-ALK-driven lung cancers or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that enhances the immune response against ALK-positive lung cancer, potentially leading to better patient outcomes.
How similar studies have performed: Previous research has shown promising results with similar vaccine approaches in preclinical models, indicating potential for success in clinical applications.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Shaw, Alice T — Dana-Farber Cancer Inst
- Study coordinator: Shaw, Alice T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.